Safety and effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen in patients with metastatic castration-resistant prostate cancer with and without visceral metastases who had received prior radium-223: a post hoc analysis of the RALU study

被引：0
|
作者：
Rahbar, Kambiz [1 ]
Essler, Markus [2 ]
Eiber, Matthias [3 ]
la Fougere, Christian [4 ]
Prasad, Vikas [5 ]
Pabst, Kim [6 ]
Fendler, Wolfgang [7 ]
Rassek, Philipp [8 ]
Hasa, Ergela [9 ]
Dittmann, Helmut [4 ]
Bundschuh, Ralph [10 ]
Kurtinecz, Milena [11 ]
Schmall, Anja [12 ]
Verholen, Frank [12 ]
Sartor, Oliver [13 ]
机构：
[1] Univ Hosp Munster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Tech Univ Munich, Munich, Germany
[4] Univ Hosp Tubingen, Dept Nucl Med & Clin Mol Imaging, Tubingen, Germany
[5] Univ Ulm, Dept Nucl Med, Ulm, Germany
[6] Univ Hosp Essen, Dept Nucl Med, West German Canc, Essen, Germany
[7] Univ Hosp Essen, Essen, Germany
[8] Univ Munster, Dept Nucl Med, Med Ctr, Munster, Germany
[9] Tech Univ Munich, Nucl Med, Klinikum Rechts Isar, Munich, Germany
[10] Univ Hosp Augsburg, Nucl Med, Fac Med, Augsburg, Germany
[11] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[12] Bayer Consumer Care, Basel, Switzerland
[13] Tulane Med Sch, Tulane Canc Ctr, New Orleans, LA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P607
引用
收藏
页数：3
相关论文
共 50 条
  • [21] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [22] Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
    Yang, Han-chung
    Chang, Li-wen
    Li, Jian-ri
    Wang, Shian-shiang
    Yang, Cheng-kuang
    Chen, Chuan-shu
    Lu, Kevin
    Chen, Cheng-che
    Wang, Shu-chi
    Lin, Chia-yen
    Cheng, Chen-li
    Ou, Yen-chuan
    Chiu, Kun-yuan
    Hung, Sheng-chun
    ANTICANCER RESEARCH, 2023, 43 (04) : 1809 - 1816
  • [23] Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study
    Kawahara, Takashi
    Miyoshi, Yasuhide
    Ninomiya, Sahoko
    Sato, Motoki
    Takeshima, Teppei
    Hasumi, Hisashi
    Makiyama, Kazuhide
    Uemura, Hiroji
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (09) : 1079 - 1084
  • [24] Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study
    Matsumoto, Takashi
    Hori, Yoshifumi
    Shiota, Masaki
    Blas, Leandro
    Nakamura, Motonobu
    Seki, Narihito
    Kuroiwa, Kentaro
    Yokomizo, Akira
    Morokuma, Futoshi
    Kiyoshima, Keijiro
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (02) : 139 - 146
  • [25] A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
    Pan, Elizabeth
    Xie, Wanling
    Ajmera, Archana
    Araneta, Arlene
    Jamieson, Christina
    Folefac, Edmund
    Hussain, Arif
    Kyriakopoulos, Christos E.
    Olson, Adam
    Parikh, Mamta
    Parikh, Rahul
    Saraiya, Biren
    Ivy, S. Percy
    Allen, Eliezer M. Van
    Lindeman, Neal I.
    Kochupurakkal, Bose S.
    Shapiro, Geoffrey I.
    McKay, Rana R.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (04) : 511 - 518
  • [26] Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).
    Sartor, A. Oliver
    la Fougere, Christian
    Essler, Markus
    Ezziddin, Samer
    Kramer, Gero
    Ellinger, Joerg
    Nordquist, Luke T.
    Sylvester, John
    Paganelli, Giovanni
    Peer, Avivit
    Boegemann, Martin
    Meltzer, Jeffrey
    Sandstrom, Per
    Song, Danny
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Conti, Peter
    George, Saby
    Tomaszewski, Jeffrey
    Song, Daniel
    Harshman, Lauren
    Nordquist, Luke
    Sandstrom, Per
    Bayh, Inga
    Babajanyan, Svetlana
    Sartor, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [28] Safety and efficacy of radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hirotsugu
    Uemura, Hiroji
    Matsubara, N.
    Kaneko, M.
    Doi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S489 - S489
  • [29] A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer
    Skelton, William P.
    Dibenedetto, Samantha W.
    Pang, Shiyi S.
    Pan, Kelsey
    Barish, Acob L.
    Nwosu-Iheme, Adaeze
    Dang, Long
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (01)
  • [30] A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
    Bryce, A. H.
    Alumkal, J. J.
    Armstrong, A.
    Higano, C. S.
    Iversen, P.
    Sternberg, C. N.
    Rathkopf, D. E.
    Loriot, Y.
    de Bono, J.
    Tombal, B.
    Abhyankar, S.
    Lin, P.
    Krivoshik, A.
    Phung, D.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2016, 27
12345